No FDA-approved GLP-1 medicine comes as a gummy. The phrase "GLP-1 gummies" covers three different products: a fibre-and-vitamin gummy for people already on a GLP-1 medicine, a supplement that claims to raise the body's own GLP-1, and a prescription gummy that contains compounded semaglutide. They differ in what they contain, who regulates them and what evidence exists. This page separates them and counts the evidence for each.
Read on 13 November 2026 from Drugs@FDA, the sellers' own pages, the FDA's statement on unapproved GLP-1 drugs, PubMed and ClinicalTrials.gov.
The three products behind one name
| What it is | What it contains | Prescription? | Reviewed by the FDA before sale? |
|---|---|---|---|
| "GLP-1 support" gummy | Fibre and vitamins | No | No. It is a dietary supplement |
| "GLP-1 booster" gummy | Plant extracts, fibre or probiotics, sold as raising the body's own GLP-1 | No | No. It is a dietary supplement |
| Compounded semaglutide gummy | Semaglutide, the active ingredient of Ozempic and Wegovy, made by a compounding pharmacy | Yes | No. Compounded drugs are not FDA-approved |
The first two contain no GLP-1 medicine. The third contains one, in a form no regulator has assessed.
What the approved list contains
Drugs@FDA, read through the openFDA service on 13 November 2026, lists these dosage forms for the seven GLP-1-type active ingredients approved in the US:
| Active ingredient | Applications | Product entries by form |
|---|---|---|
| Semaglutide | 6 | 22 injection, 12 oral tablet |
| Tirzepatide | 2 | 48 injection |
| Liraglutide | 14 | 14 injection |
| Dulaglutide | 1 | 4 injection |
| Exenatide | 5 | 9 injection |
| Lixisenatide | 2 | 3 injection |
| Orforglipron | 1 | 6 oral tablet |
| Total | 31 | 100 injection, 18 oral tablet, 0 chewable or gummy |
An eighth, albiglutide, is listed only as a discontinued injection and is not counted.
The check on that zero. A search of the same database for chewable dosage forms returns 128 applications for other drugs. The database does record chewables. None of them is a GLP-1.
The tablets that do exist are on the oral GLP-1 page, each with its own label rules.
Group one: fibre-and-vitamin "support" gummies
These are sold to people who are already taking a GLP-1 medicine. They make no claim to act like one.
Vitafusion's GLP-1 Support gummy is the clearest example. Its maker's page describes it as packing "6g of fiber plus Vitamin D, B12, and Folate into every serving", with a serving of three gummies a day, "helping to fill the nutritional gaps that come with eating less". The page listed a 90-gummy bottle at $13.99 and showed it as out of stock on the day of reading.
That is a fibre supplement with three vitamins, carrying the GLP-1 name as a description of its intended buyer. Nothing on the page says it affects weight or GLP-1. What the labels of the medicines themselves say about constipation and nutrition is on the constipation page and the GLP-1 diet page.
Group two: "boost your own GLP-1" gummies
These are sold on a different premise: that an ingredient prompts the gut to release more of its own GLP-1. They do not contain the hormone or a drug that mimics it.
One widely advertised brand in this category does not sell its GLP-1 product as a gummy. Lemme's GLP-1 product, Lemme Reset, is a capsule, and its page states: "Reset does not contain GLP-1 or synthetic GLP-1 and is not a GLP-1 agonist drug." The gummy versions come from smaller sellers.
An NBC News report of 22 April 2025 described "fruit punch-flavored gummies" among the supplements claiming to raise GLP-1, and listed berberine, chromium and saffron extract among the ingredients appearing on these labels.
The evidence for those ingredients does not change with the format. This site has set it out already:
- Berberine. The largest trial, 337 adults for six months, found no significant difference from placebo in visceral or liver fat. The full record is on GLP-1 supplements.
- Branded formulas. One randomised trial sits behind one named formula, and the trial formula is not the product sold. See GLP-1 boosters.
- The premise itself. The body's own GLP-1 has a half-life of 1.5 to 2 minutes, as the liraglutide label states. The reasoning is on natural GLP-1.
One limit on this section. A seller's collection page for GLP-1 gummies returned a rate-limit error when this page was researched. It was not retried and is not quoted, so no specific "booster" gummy label is reproduced here.
Group three: the compounded semaglutide gummy
This is the one product in the category that contains a GLP-1 drug.
The telehealth company Eden has marketed a compounded semaglutide gummy since at least February 2025. A promotional article distributed by NewsUSA on 10 February 2025, which quotes the company's chief executive, describes "a compounded semaglutide gummy, available through independent licensed providers and compounding pharmacies", sold within a programme priced at "$246 per month".
The same article carries the most useful sentence in the category, in material written to promote the product. Of alternative formats such as the gummy, it says: "efficacy and safety data are limited."
Three things are on the record about a product of this kind:
- It is not FDA-approved. The FDA's page on unapproved GLP-1 drugs, current as of 1 October 2026, says compounded drugs are not FDA-approved, and that the agency "does not review compounded drugs for safety, effectiveness or quality before they are marketed." The page does not mention gummies specifically.
- The FDA has warned the company about its marketing. A warning letter dated 8 June 2026 (MARCS-CMS 728279) told Eden Health International that its website's presentation of compounded semaglutide and tirzepatide was false or misleading on two points: labels pictured with the Eden name, "suggesting Eden is the compounder of those drugs when in fact it is not", and a claim that the products came from "FDA-licensed" facilities. The letter does not name the gummy or any dosage form.
- Absorption by mouth is the hard part, and nothing is published for a gummy. The approved semaglutide tablets have an absolute bioavailability of roughly 0.4% to 2% on their own labels, depending on the tablet, against 89% for the injection, and the labels set a fasting routine around each dose. Those figures are on GLP-1 pill vs injection. No published study was found measuring how much semaglutide a gummy delivers.
What this page could not confirm. Eden's own product page refused the request when this page was researched, so whether the gummy is on sale today, and at what price, is not confirmed here. The wider picture on compounded versions is on compounded semaglutide.
The trial count
Searches run on 13 November 2026:
| Source and search | Records | What they are |
|---|---|---|
| PubMed: gummy or gummies, with GLP-1 or semaglutide, in title or abstract | 1 | A 10-person pilot of maqui berry gummies in adults with overweight or obesity (Int J Mol Sci, October 2026) |
| PubMed: gummy or gummies, with weight loss or obesity | 22 | Not read one by one for this page |
| ClinicalTrials.gov: gummy or gummies, with GLP-1, semaglutide, tirzepatide or liraglutide | 2 | The maqui berry study, and a study of flavour release and fullness. Neither tests a GLP-1 drug in a gummy or a product sold as a GLP-1 gummy |
| ClinicalTrials.gov: gummy as the intervention, obesity or overweight as the condition | 7 | One is a weight trial of a gummy: polydextrose fibre gummies against placebo, 96 adults, 24 weeks, company-sponsored, not yet recruiting (NCT07758387) |
The one published record is worth reading closely because it is the only one. Ten adults ate white bread alone, then with each of two maqui berry gummies. GLP-1 was higher after one gummy, but "changes in GLP-1 from baseline did not differ significantly among conditions". The authors wrote that the small sample, fixed order and lack of a placebo gummy "limit causal attribution".
The check on these counts. PubMed holds 1,242 records mentioning gummy or gummies, and ClinicalTrials.gov returns 128 studies for a gummy intervention with no condition set, though some of those are dental studies of a "gummy smile". The searches do find gummy research. Almost none of it concerns GLP-1.
Adverts with famous faces
Weight-loss products are a regular subject of fake celebrity adverts. A Federal Trade Commission consumer alert of 24 April 2024 says scammers are "using fake celebrity and influencer testimonials and endorsements", with doctored video and audio, and names weight-loss products among the examples. The alert's own text does not mention gummies or GLP-1.
What is not established
- No trial of any product sold as a GLP-1 gummy was found in the searches above, in either the supplement or the compounded group.
- No absorption data for semaglutide in a gummy have been published.
- No count of how many such products are on sale is offered here. One seller page was rate-limited and one refused the request.
- The FDA has made no statement about gummies specifically on its unapproved GLP-1 drugs page as read for this article.
A question about any of these products belongs with a pharmacist or prescriber — particularly for anyone already taking a GLP-1 medicine or other prescription drugs. This page reports what the products are and what has been tested. It does not say which, if any, a person should use.
Sources
- Drugs@FDA via openFDA, read 13 November 2026: product entries for semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide and orforglipron; control search for chewable dosage forms (128 applications).
- Vitafusion, GLP-1 Support Fiber Plus Gummy, 90 Gummies, read 13 November 2026.
- Lemme, Lemme Reset product page, read 13 November 2026.
- NBC News, "What to know about GLP-1 supplements for weight loss", Lindsey Leake, 22 April 2025.
- NewsUSA, "Goodbye Needles, Hello Convenience: Exploring Compounded Semaglutide", 10 February 2025 (promotional article, read on a syndication site that labels it third-party content).
- FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss, content current as of 1 October 2026.
- FDA warning letter to Eden Health International Inc. dba Eden, 8 June 2026, MARCS-CMS 728279.
- Acevedo-Hernández P et al., International Journal of Molecular Sciences 2026, PMID 42941909. ClinicalTrials.gov NCT07758387, NCT07373795, NCT03621358.
- Federal Trade Commission, "Did a celebrity really endorse THAT? Maybe not", 24 April 2024.
